PUBLISHER: Allied Market Research | PRODUCT CODE: 1344330
PUBLISHER: Allied Market Research | PRODUCT CODE: 1344330
According to a new report published by Allied Market Research, titled, "Artificial Organs and Bionic Implants Market," The artificial organs and bionic implants market was valued at $44.4 billion in 2022, and is estimated to reach $92.1 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032.
Bionic implants, on the other hand, are devices that integrate electronic or mechanical components with natural tissues to restore or enhance bodily functions. They are often used to replace or augment sensory organs, such as cochlear implants for hearing loss or retinal implants for vision impairment. Bionic limbs, also known as prosthetics, are artificial limbs that can be controlled by neural signals or muscle contractions to provide mobility and dexterity for individuals with limb loss or limb dysfunction.
Both artificial organs and bionic implants rely on advancements in technology, such as biocompatible materials, sensors, actuators, and control systems, to function effectively. These devices can significantly improve the quality of life for individuals with medical conditions, allowing them to regain lost functionality or compensate for impairments. However, it is important to note that while artificial organs and bionic implants can be highly beneficial, they may not fully replicate the natural functions of the organs they replace and may require ongoing monitoring and maintenance.
Major factors that drive the growth of the global artificial organs and bionic implants market include rapid advancements in artificial organs and bionic implants; an increase in the number of patients suffering from arthritis and blindness and a rise in the number of road accidents and injuries. For instance, according to the data by World Health Organization (WHO), in June 2022, road traffic injury was the leading cause of death among children and young adults aged 5-29 years. As per the same source, approximately 1.3 million people die each year and 20 to 50 million are injured or disabled as a result of road traffic crashes.
However, the high cost associated with implant procedures, and lack of surgical professionals are expected to restrict the growth of artificial organs and the bionic implants market. On the contrary, the surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future.
The global artificial organs and bionic implants market is segmented on the basis of type, technology, end-user, and region. On the basis of type, the market is classified into orthopedic bionics, ear bionics, and others. The orthopedic bionics segment is further bifurcated into the bionic hand, bionic leg, and others (bionic limb, bionic finger, bone growth stimulators). Depending on technology, it is bifurcated into electronic and mechanical. By end user, it is segregated into hospitals, ambulatory surgical centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Abbott Laboratories, Berlin Heart GmbH, Boston Scientific Corporation, Cochlear Limited, Edward Lifesciences Corporations, Jarvik Heart, Inc., Johnson & Johnson, Medtronic plc, SynCardia Systems, LLC, and Zimmer Biomet Holding Inc. These major players have adopted product approval, agreement, acquisition, and product launch as key developmental strategies to improve the product portfolio of the artificial organs and bionic implants market.